Trial completion date • Trial initiation date • Trial primary completion date • Pan tumor
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506